Prosecution Insights
Prosecution Insights
Technology area: Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Immunsys Inc. is active in the Medical Devices & Mechanical Engineering technology area, currently managing 2 pending office actions. This suggests a portfolio with multiple ongoing developments that are being scrutinized by the patent office. These actions are distributed across 2 distinct examiners, which indicates that the company's innovations are being evaluated from different perspectives. This distribution requires a flexible prosecution strategy that can address the different standards and expectations of the examiners within the Medical Devices & Mechanical Engineering sector to ensure that both applications move toward allowance.
ZINK, AMANDA L is identified as the busiest examiner for the portfolio, currently handling 1 pending action. The involvement of 2 distinct art units means that the company must be prepared for potentially different interpretations of what constitutes patentable subject matter. The 2 pending office actions represent the current challenges the company must navigate to secure its intellectual property in this field. Practitioners should focus on the specific feedback from ZINK, AMANDA L and the other examiner to maintain a cohesive strategy across the entire Medical Devices & Mechanical Engineering portfolio, as the resolution of these cases will significantly impact the company's protected status.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZINK, AMANDA L | 1 | 85.2% | +3.1% |
| MCGRATH, ERIN E | 1 | 60.1% | +28.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324225 | Cancer Immunotherapy by Radiofrequency Electrical Membrane Breakdown (RF-EMB) | ZINK, AMANDA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17490161 | Radio-Frequency Electrical Membrane Breakdown for the Treatment of High Risk and Recurrent Prostate Cancer, Unresectable Pancreatic Cancer, Tumors of the Breast, Melanoma or Other Skin Malignancies, Sarcoma, Soft Tissue Tumors, Ductal Carcinoma, Neoplasia, and Intra and Extra Luminal Abnormal Tissue | MCGRATH, ERIN E | — |
| Art Unit | Apps |
|---|---|
| 3794 | 1 |
| 3771 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18324225 | Cancer Immunotherapy by Radiofrequency Electrical Membrane Breakdown (RF-EMB) | ZINK, AMANDA L | 3794 | DP | Non-Final OA | — | Pending | May 26, 2023 |
| 17490161 | Radio-Frequency Electrical Membrane Breakdown for the Treatment of High Risk and Recurrent Prostate Cancer, Unresectable Pancreatic Cancer, Tumors of the Breast, Melanoma or Other Skin Malignancies, Sarcoma, Soft Tissue Tumors, Ductal Carcinoma, Neoplasia, and Intra and Extra Luminal Abnormal Tissue | MCGRATH, ERIN E | 3771 | §103 | Non-Final OA | — | Pending | Sep 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial